Ben Walker

Ben is a global biopharma business development professional who has been strategic advisor to leading companies, institutions and start-ups.
Prior to joining Novatio, Ben ran business development for a U.S.
technology accelerator, ACTUS Biotechnologies, where he played an integral role in strategic partnering for certain transdermal and tumor-targeting technologies licensed from UCSB and Sanford Burnham by its portfolio companies, Convoy and EnduRx, securing a key licensing deal in 2013.
Since 2005, Ben has run a Hong Kong-based consulting firm, Nexanova Ltd, and worked on over 40 projects covering oncology, cardiovascular disease, neurology, dermatology and infectious diseases for leading bio-pharma clients, including Debiopharm, Green Cross, and Samyang Pharmaceutical.
He has also worked closely with universities and their spin-off companies in Hong Kong and Korea, including HKUST, CUHK, SNU, and Yonsei.
Prior to entering the bio-pharma industry, Ben was China Business Development Manager for the animal nutrition division of Associated British Foods plc, where he specialized in acquisitions and set up two joint ventures in China.
Ben holds an MA (Hons) degree in Chinese and Japanese from Edinburgh University and an MBA from Manchester Business School.
He is fluent in Mandarin.